Cetera Trust Company N.A lowered its position in shares of MetLife, Inc. (NYSE:MET – Free Report) by 55.4% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 12,050 shares of the financial services provider’s stock after selling 14,960 shares during the period. Cetera Trust Company N.A’s holdings in MetLife were worth $1,135,000 as of its most recent SEC filing.
A number of other hedge funds have also recently modified their holdings of the business. Nvwm LLC grew its position in shares of MetLife by 655.3% in the 3rd quarter. Nvwm LLC now owns 287 shares of the financial services provider’s stock worth $27,000 after buying an additional 249 shares during the period. Mowery & Schoenfeld Wealth Management LLC purchased a new position in MetLife during the 2nd quarter valued at about $26,000. Burk Holdings LLC purchased a new position in MetLife during the 2nd quarter valued at about $27,000. Highland Investment Advisors LLC bought a new stake in MetLife during the second quarter worth about $30,000. Finally, Elevation Wealth Partners LLC boosted its stake in MetLife by 123.5% during the third quarter. Elevation Wealth Partners LLC now owns 362 shares of the financial services provider’s stock worth $34,000 after acquiring an additional 200 shares in the last quarter. Institutional investors own 94.99% of the company’s stock.
Insider Transactions at MetLife
In other news, CEO Michel Khalaf sold 187,425 shares of the company’s stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $102.97, for a total value of $19,299,152.25. Following the transaction, the chief executive officer owned 759,013 shares in the company, valued at approximately $78,155,568.61. This represents a 19.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.40% of the company’s stock.
Analysts Set New Price Targets
A number of equities research analysts have weighed in on the stock. Keefe, Bruyette & Woods upped their price objective on shares of MetLife from $105.00 to $108.00 and gave the stock an “outperform” rating in a report on Tuesday, August 11th. Mizuho lifted their target price on shares of MetLife from $112.00 to $117.00 and gave the company an “outperform” rating in a report on Thursday. Argus boosted their price target on MetLife from $93.00 to $109.00 and gave the stock a “buy” rating in a research report on Wednesday, September 2nd. Morgan Stanley upped their price target on MetLife from $103.00 to $111.00 and gave the stock an “overweight” rating in a research note on Monday, August 24th. Finally, Wells Fargo & Company raised their price objective on MetLife from $110.00 to $113.00 and gave the company an “overweight” rating in a research report on Thursday. Fourteen analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $107.12.
Check Out Our Latest Analysis on MET
Key Headlines Impacting MetLife
Here are a few of the latest headlines about MET:
- Positive Sentiment: Analysts raised their price targets. Mizuho lifted its target to $117 from $112 and maintained an “outperform” rating; Wells Fargo raised its target to $113 from $110 and kept an “overweight” rating. The higher targets indicate continued analyst confidence and potential upside. Mizuho price target article Wells Fargo price target article
- Neutral Sentiment: MetLife earned workplace recognition. The company was named among the 2026 Fortune World’s Best Workplaces and topped U.S.-based financial services and insurance companies on the list. This may support its reputation as an employer, though the direct impact on near-term earnings is unclear. Fortune workplace ranking article
- Negative Sentiment: CEO Michel Khalaf sold 187,425 shares for about $19.3 million, reducing his position by 19.8%. Insider sales can concern investors, although Khalaf retained 759,013 shares after the transaction. CEO share sale article
MetLife Price Performance
MET opened at $102.67 on Monday. The stock has a 50-day moving average price of $98.75 and a 200-day moving average price of $86.90. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.21 and a quick ratio of 0.21. The firm has a market cap of $64.52 billion, a PE ratio of 13.39, a P/E/G ratio of 0.97 and a beta of 0.79. MetLife, Inc. has a 1 year low of $67.33 and a 1 year high of $106.72.
MetLife (NYSE:MET – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The financial services provider reported $2.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.01. MetLife had a net margin of 6.21% and a return on equity of 25.71%. The company had revenue of $20.52 billion for the quarter, compared to analysts’ expectations of $19.86 billion. During the same quarter in the previous year, the business posted $2.34 EPS. MetLife’s revenue was up 18.2% compared to the same quarter last year. Sell-side analysts predict that MetLife, Inc. will post 9.91 earnings per share for the current fiscal year.
MetLife announced that its Board of Directors has authorized a stock buyback plan on Wednesday, August 5th that permits the company to repurchase $3 billion in outstanding shares. This buyback authorization permits the financial services provider to purchase up to 4.8% of its shares through open market purchases. Share buyback plans are typically a sign that the company’s leadership believes its stock is undervalued.
MetLife Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 3rd will be issued a $0.5925 dividend. The ex-dividend date of this dividend is Tuesday, November 3rd. This represents a $2.37 annualized dividend and a yield of 2.3%. MetLife’s payout ratio is 30.90%.
MetLife Company Profile
MetLife, Inc. is a global financial services company best known for providing insurance, employee benefits and retirement-related products. Its offerings include life, dental and disability insurance, annuities, and products and services designed to help individuals and employers plan for financial protection and retirement. The company serves individuals, businesses and institutions in the United States and international markets, including countries in Latin America, Asia, Europe and the Middle East.
Further Reading
- Five stocks we like better than MetLife
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding MET? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MetLife, Inc. (NYSE:MET – Free Report).
Receive News & Ratings for MetLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife and related companies with MarketBeat.com's FREE daily email newsletter.
